These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Peritoneal dialysis in patients with diabetes mellitus]. Plum J Dtsch Med Wochenschr; 2005 Sep; 130(36):2035-8. PubMed ID: 16143936 [No Abstract] [Full Text] [Related]
3. Management of glycemia in patients with diabetes mellitus and CKD. Lubowsky ND; Siegel R; Pittas AG Am J Kidney Dis; 2007 Nov; 50(5):865-79. PubMed ID: 17954300 [No Abstract] [Full Text] [Related]
4. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes. Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199 [TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones: a novel class of drugs for the prevention of diabetic nephropathy? Zheng F; Guan Y Kidney Int; 2007 Dec; 72(11):1301-3. PubMed ID: 18004308 [TBL] [Abstract][Full Text] [Related]
6. The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus. de Boer RA; Martens FM; Kuipers I; Boomsma F; Visseren FL J Hum Hypertens; 2010 Jan; 24(1):74-6. PubMed ID: 19847195 [No Abstract] [Full Text] [Related]
7. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes. Lehmann DF; Lohray BB J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500 [No Abstract] [Full Text] [Related]
8. Comparisons of peritoneal transport between insulin-dependent and noninsulin-dependent and noninsulin-dependent diabetic peritoneal dialysis patients. Lin JJ; Wadhwa NK; Suh H; Cabralda T Perit Dial Int; 1997; 17(2):208-9. PubMed ID: 9159849 [No Abstract] [Full Text] [Related]
9. Effect of short-term rosiglitazone therapy in peritoneal dialysis patients. van Hooland S; Boey O; Van der Niepen P; Van den Branden C; Verbeelen D Perit Dial Int; 2009; 29(1):108-11. PubMed ID: 19164260 [No Abstract] [Full Text] [Related]
10. [The protective role of PPARgamma in diabetic nephropathy]. Zang HL; Wang CJ; Yang JC Sheng Li Ke Xue Jin Zhan; 2010 Dec; 41(6):435-8. PubMed ID: 21416961 [No Abstract] [Full Text] [Related]
11. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Fogo AB Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479 [TBL] [Abstract][Full Text] [Related]